Reno, NV – Equazen® Pro, the “no prescription needed” medical food clinically shown to improve focus and academic performance within 12 weeks†, gained national distribution through major drug and mass-market retailers, both online and in thousands of in-store locations, in June, 2022. With ADHD (Attention-deficit/hyperactivity disorder) affecting 6.1 million children in the United States and the diagnosis rate up a whopping 42% between 2003 and 2011^[1], this condition is a troubling issue for patients, parents, and teachers.

Over 15 Years of Research and Clinical Trials

Backed by 15 years of research and 19 clinical research articles, Equazen® Pro is well established in Europe. With its entry into the US, SFI Health is offering not only easy-to-swallow softgels, but also jelly chews which are appropriate for children aged three and up.

In the US, almost 70% of children with ADHD are on medication^[2]and the number of prescriptions jumped to 41.4 million last year, up 10.4% from 2020.^[3] “Our purpose in bringing Equazen® Pro to the US is to provide a clinically proven, non-prescription, nutrition solution to help reduce ADHD symptoms. Studies show that Equazen® Pro is safe and effective to use as nutritional support along with common prescription ADHD medications.^[4] What excites us most is advancing options available to parents, patients, and healthcare professionals,” says Divya Ramakrishnan, General Manager for Americas at SFI Health.

Since ADHD is often associated with impaired omega fatty acid balance, Equazen®️ Pro works by providing an optimal balance of both omega-3 and omega-6 fatty acids for the dietary management of ADHD. ^†

Equazen® Pro for ADHD Support is now available online and in more than 4,000 retail stores across the United States in two easy to use formats, softgels and delicious, fruit-flavored jelly chews.

The jelly chews are a first-of-its-kind medical food for children and adults with attention-deficit/hyperactivity disorder (ADHD) and offer a high dose of omega-3 fatty acids.  Due to the unique formulation, the jelly-like chews are easy to digest.

A big step forward for SFI Health

“This is a big step forward for SFI Health,” explained Robert Hendriks, CEO of SFI Health. “Launching Equazen® to the US, drastically improves access to a product which has been clinically shown to support cognitive health. It is designed to address fatty acid deficiencies common in people with ADHD and some related neurodiverse conditions that cannot be resolved by normal diet modifications alone.”

“We are excited to step into the chewable category with Equazen® Pro Jelly Chews,” said SFI Health’s Americas General Manager Divya Ramakrishnan, “because they carry a clinically relevant dosage, which was not possible with gummies. With their natural fruit flavour and no fishy smell, taste, or burps, Jelly Chews will improve compliance among children who have difficulties swallowing softgels.”

This product mirrors the way we eat food, including chewing, swallowing, and digesting, and delivers tiny oil droplets of nutrition stabilised in an emulsion, similar to the way fatty acids are stored in fish. These tiny droplets increase surface contact in the digestive system, increasing absorption and bioavailability.

†EQUAZEN® PRO is a medical food to address fatty acid deficiencies common in people with ADHD and some related neurodiverse conditions that cannot be resolved by normal diet modification alone. In clinical trials* among kids and teens with ADHD, the EQUAZEN® PRO formula showed on average significant improvements in focus, attention, academic performance, and balanced mood. USE UNDER MEDICAL SUPERVISION. *19 clinical research studies.

^[1] Visser SN, Danielson ML, Bitsko RH, et al. 2003-2011. Journal of the American Academy of Child & Adolescent Psychiatry 2014; 53:34–46.e2

^[2] https://www.nimh.nih.gov/health/statistics/attention-deficit-hyperactivity-disorder-adhd

^[3] Walmart, CVS Pharmacies Have Blocked or Delayed Telehealth Adderall Prescriptions – WSJ

^[4]Barragán E, Breuer D, Döpfner M. Journal of Attention Disorders. 2017;21(5):433-441.